Affordable Access

Publisher Website

A rapid, accurate and robust UHPLC–MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies

Journal of Pharmaceutical and Biomedical Analysis
DOI: 10.1016/j.jpba.2013.05.019
  • Bms-927711
  • Cgrp Antagonist
  • Quantitation
  • Uhplc–Ms/Ms
  • N-Carbamoyl Glucuronide
  • Stability


Abstract BMS-927711 is a calcitonin gene-related peptide (CGRP) receptor antagonist that is being developed for the treatment of migraine. A rapid, accurate and robust assay was developed and validated for the quantitation of BMS-927711 in rat, monkey, rabbit and mouse plasma using ultra high performance liquid chromatography with tandem mass spectrometry (UHPLC–MS/MS). A simplified method screening strategy was utilized that included a liquid–liquid extraction (LLE) methodology and eleven LC columns (ten sub-2μm UHPLC columns and one 2.6μm HPLC column) for screening with emphasis on the removal of phospholipids, avoidance of metabolite interference and ruggedness of LC conditions. A stable isotope labeled [13C2, D4]-BMS-927711 was used as the internal standard, and 50μL of plasma samples were used for extraction by automated LLE with methyl tert-butyl ether (MTBE) in 96-well format. Chromatographic separation was achieved with an isocratic elution and a gradient column wash on a Waters Acuity UPLC® BEH C18 column (2.1mm×50mm, 1.7μm) with run time of 3.7min. Positive electrospray ionization was performed using selected reaction monitoring (SRM) with transitions of m/z 535>256 for BMS-927711 and m/z 541>256 for [13C2, D4]-BMS-927711. The standard curve, which ranged from 3.00 to 3000ng/mL for BMS-927711, was fitted to a 1/x2 weighted linear regression model. The intra-assay precision was within 5.2% CV, inter-assay precision was within 5.9% CV, and the assay accuracy was within ±5.2% deviation (%Dev) of the nominal values in all the species. The stability of an N-carbamoyl glucuronide metabolite was carefully investigated, and the conversion of this metabolite to BMS-927711 was minimal and manageable without a stabilization procedure. The method was successfully applied to multiple non-clinical toxicokinetic studies in different species in support of the investigative new drug (IND) filing.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times